Nanoemulsion loaded with lycobetaine-oleic acid ionic complex: Physicochemical characteristics, in vitro, in vivo evaluation, and antitumor activity

International Journal of Nanomedicine

Volumn 8, Issue , 2013, Pages 1959-1973

  Zhao, Hui ^a   Lu, Hua ^a   Gong, Tao ^a   Zhang, Zhirong ^a  

^a SICHUAN UNIVERSITY   (China)

Author keywords

Antitumor activity; In vivo studies; Lycobetaine; Nanoemulsion; Oleic acid; Polyethylene glycol

Indexed keywords

ANTINEOPLASTIC AGENT; LYCOBETAINE; LYCOBETAINE OLEIC ACID IONIC COMPLEX; NANOCARRIER; PEGYLATED LYCOBETAINE OLEIC ACID IONIC COMPLEX; PHENANTHRIDINE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CHEMICAL PROCEDURES; COMPLEX FORMATION; CONTROLLED STUDY; DIFFERENTIAL SCANNING CALORIMETRY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG EFFECT; DRUG FORMULATION; DRUG HALF LIFE; DRUG RELEASE; DRUG SCREENING; DRUG SOLUBILITY; DRUG STRUCTURE; DRUG TISSUE LEVEL; FEASIBILITY STUDY; HIGH PRESSURE HOMOGENIZATION; IN VITRO STUDY; IN VIVO STUDY; LEWIS CARCINOMA; LIPOPHILICITY; LUNG METASTASIS; MALE; MAXIMUM PLASMA CONCENTRATION; MEAN RESIDENCE TIME; NANOEMULSION; NANOENCAPSULATION; NONHUMAN; PARTICLE SIZE; PHYSICAL CHEMISTRY; PROCESS OPTIMIZATION; RAT; SCALE UP; STRUCTURE ACTIVITY RELATION; SURVIVAL TIME; ZETA POTENTIAL;

ANTITUMOR ACTIVITY; IN VIVO STUDIES; LYCOBETAINE; NANOEMULSION; OLEIC ACID; POLYETHYLENE GLYCOL;

AMARYLLIDACEAE ALKALOIDS; ANIMALS; ANTINEOPLASTIC AGENTS; CALORIMETRY, DIFFERENTIAL SCANNING; CELL LINE, TUMOR; CELL PROLIFERATION; EMULSIONS; INDOLIZINES; MALE; MICE; NANOSTRUCTURES; OCTANOLS; OLEIC ACID; RATS; RATS, WISTAR; SOLUBILITY; SURVIVAL ANALYSIS; TISSUE DISTRIBUTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84878192040     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/IJN.S43892     Document Type: Article

References (36)

1. Weng ZY, Wang ZY, Yan XM. A new antitumour agent ungeremine (AT-1840) and its structure-activity relationship. Yao Xue Xue Bao. 1982;17(10):744-749. Chinese [with English abstract].
2. Ghosal S, Singh SK, Kumar Y, Unnikrishnan S, Chattopadhyay S. The role of ungeremine in the growth-inhibiting and cytotoxic effects of lycorine: evidence and speculation. Planta Med. 1988;54(2): 114-116.
3. Zhang SY, Lu FL, Yang JL, Wang LJ, Xu B. Effect on animal tumors and toxicity of lycobetaine acetate (author's translation). Zhongguo Yao Li Xue Bao. 1981;2(1):41-45. Chinese [with English abstract].
4. Barthelmes HU, Niederberger E, Roth T, et al. Lycobetaine acts as a selective topoisomerase II beta poison and inhibits the growth of human tumor cells. Br J Cancer. 2001;85(10):1585-1591.
5. Casu L, Cottiglia F, Leonti M, et al. Ungeremine effectively targets mammalian as well as bacterial type I and type II topoisomerases. Bioorg Med Chem Lett. 2011;21(23):7041-7044.
6. Wu Z, Chen Y, Feng X, Xia B. Pharmacology study of medicinal plant alkaloids of Amaryllidaceae medicinal plants. Chinese Wild Plant Resources. 2008;27(5):26-31.
7. Qinghe H, et al. Lycobetaine (AT-1840) in the comprehensive treatment of gynecological late malignant tumor - with 43 cases summarized. Zhejiang combine traditional Chinese and western medicine magazine. 1997;7(3):3. Available at http://www.cqvip.com/qk/98552x/199703/2474273.html. Chinese.
8. Liang G, Xu Y, Xu B. Pharmacokinetics of ungeremine acetate in rats. Chinese Pharmacological Bulletin. 1997;13(1):3. Available at http://en.cnki.com.cn/Article_en/CJFDTOTAL-YAOL701.011.htm. Chinese
9. Fernández-Campos F, Clares NB, López SO, Alonso MC, Calpena Campmany AC. Evaluation of novel nystatin nanoemulsion for skin candidosis infections. Mycoses. 2013;56(1):70-81.
10. Xiang QY, Wang MT, Chen F, et al. Lung-targeting delivery of dexamethasone acetate-loaded solid lipid nanoparticles. Arch Pharm Res. 2007;30(4):519-525.
11. Müller RH, Shegokar R, Keck CM. Twenty years of lipid nanoparticles (SLN and NLC): present state of development and industrial applications. Curr Drug Discov Technol. 2011;8(3):207-227.
12. Divsalar A, Saboury AA, Nabiuni M, Zare Z, Kefayati ME, Seyedarabi A. Characterization and side effect analysis of a newly designed nanoemulsion targeting human serum albumin for drug delivery. Colloids Surf B Biointerfaces. 2012;98:80-84.
13. Storm G, Belliot S, Daemen T, Lasic D. Surface modification of nano-particles to oppose uptake by the mononuclear phagocyte system. Adv Drug Deliv Rev. 1995;17(1):31-48.
14. Sadzuka Y, Nakade A, Hirama R, et al. Effects of mixed polyethyleneglycol modification on fixed aqueous layer thickness and antitumor activity of doxorubicin containing liposome. Int J Pharm. 2002;238(1-2): 171-180.
15. Siddiqui A, Gupta V, Liu YY, Nazzal S. Doxorubicin and MBO-asGCS oligonucleotide-loaded lipid nanoparticles overcome multidrug resistance in adriamycin-resistant ovarian cancer cells (NCI/ADR-RES). Int J Pharm. 2012;431(1-2):222-229.
16. Higashiyama M, Inada K, Ohtori A, Kakehi K. NMR analysis of ion-pair formation between timolol and sorbic acid in ophthalmic preparations. J Pharm Biomed Anal. 2007;43(4):1335-1342.
17. Ma P, Dong X, Swadley CL, et al. Development of idarubicin and doxorubicin solid lipid nanoparticles to overcome Pgp-mediated multiple drug resistance in leukemia. J Biomed Nanotechnol. 2009;5(2): 151-161.
18. Zhang X, Sun X, Li J, Zhang X, Gong T, Zhang Z. Lipid nanoemulsions loaded with doxorubicin-oleic acid ionic complex: characterization, in vitro, and in vivo studies. Pharmazie. 2011;66(7):496-505.
19. Pontes-Arruda A. Biological benefits of an oleic acid-rich lipid emulsion for parenteral nutrition. Clinical Nutrition Supplements. 2009;4(1):19-23.
20. Olbrich C, Gessner A, Kayser O, Müller RH. Lipid-drug-conjugate (LDC) nanoparticles as novel carrier system for the hydrophilic antitrypanosomal drug diminazenediaceturate. J Drug Target. 2002;10(5): 387-396.
21. Olbrich C, Gessner A, Schröder W, Kayser O, Müller RH. Lipid-drug conjugate nanoparticles of the hydrophilic drug diminazene-cytotoxicity testing and mouse serum adsorption. J Control Release. 2004;96(3): 425-435.
22. Quintanar-Guerrero D, Allémann E, Fessi H, Doelker E. Applications of the ion-pair concept to hydrophilic substances with special emphasis on peptides. Pharm Res. 1997;14(2):119-127.
23. Kalinkova GN. Complexation: Noncyclodextrins. In: Swarbrick J, editor. Encyclopedia of Pharmaceutical Technology, 3rd ed. New York: Informa Healthcare USA Inc; 2006:697-706.
24. Kanjilal S, Kaki SS, Rao BV, et al. Hypocholesterolemic effects of low-calorie structured lipids on rats and rabbits fed on normal and atherogenic diet. Food Chem. 2013;136(1):259-265.
25. Wabel C. Influence of Lecithin on Structure and Stability of Parenteral Fat Emulsions [doctoral dissertation]. Frankfurt, Alemania: University of Erlangen-Nuremberg; 1998.
26. Zhao D, Gong T, Fu Y, et al. Lyophilized Cheliensisin A submicron emulsion for intravenous injection: characterization, in vitro, and in vivo antitumor effect. Int J Pharm. 2008;357(1-2):139-147.
27. Zhao Y, Wang L, Yan M, et al. Repeated injection of PEGylated solid lipid nanoparticles induces accelerated blood clearance in mice and beagles. Int J Nanomedicine. 2012;7:2891-2900.
28. Sriwongsitanont S, Ueno M. Effect of a PEG lipid (DSPE-PEG2000) and freeze-thawing process on phospholipid vesicle size and lamellarity. Colloid Polym Sci. 2004;282(7):753-760.
29. Needham D, Stoicheva N, Zhelev DV. Exchange of mono- oleoylphosphatidylcholine as monomer and micelle with membranes containing poly(ethylene glycol)-lipid. Biophys J. 1997;73(5): 2615-2629.
30. Siepmann J, Peppas NA. Modeling of drug release from delivery systems based on hydroxypropyl methylcellulose (HPMC). Adv Drug Deliv Rev. 2001;48(2-3):139-157.
31. Zhang Y, Huo M, Zhou J, et al. DDSolver: an add-in program for modeling and comparison of drug dissolution profiles. AAPS J. 2010;12(3): 263-271.
32. Moghimi SM, Hunter AC, Murray JC. Long-circulating and target- specific nanoparticles: theory to practice. Pharmacol Rev. 2001;53(2): 283-318.
33. Vonarbourg A, Passirani C, Saulnier P, Benoit JP. Parameters infuencing the stealthiness of colloidal drug delivery systems. Biomaterials. 2006;27(24):4356-4373.
34. Vonarbourg A, Passirani C, Saulnier P, Simard P, Leroux JC, Benoit JP. Evaluation of pegylated lipid nanocapsules versus complement system activation and macrophage uptake. J Biomed Mater Res A. 2006;78(3): 620-628.
35. Mosqueira VC, Legrand P, Gulik A, et al. Relationship between complement activation, cellular uptake, and surface physicochemical aspects of novel PEG-modified nanocapsules. Biomaterials. 2001;22(22): 2967-2979.
36. Moghimi SM, Szebeni J. Stealth liposomes and long-circulating nanoparticles: critical issues in pharmacokinetics, opsonization and protein-binding properties. Prog Lipid Res. 2003;42(6):463-478.